Generic tofacitinib (Xeljanz®) has officially entered the market – an important shift in the JAK inhibitor category. With launches across multiple manufacturers in early June, we’re now seeing the first meaningful opportunity to introduce competition into a class that has historically driven significant specialty spend.
What does this mean for plan sponsors?
- Near-term savings opportunity as generics begin to disrupt a high-cost category.
- Formulary strategy inflection point – revisiting step therapy, preferred positioning, and UM criteria will be critical.
- Pipeline momentum with additional entrants expected, accelerating competitive pressure.
At ProAct, our focus is clear:
- Rapid evaluation and adoption of clinically appropriate generics.
- Thoughtful formulary alignment to drive savings without compromising care.
- Leveraging competition to bend the specialty cost curve.
This is another reminder that proactive formulary strategy – not just market events – ultimately determines client impact.
